Buprenorphine Induction and Naloxone Distribution Program-Combined With Warm Hand-Off Referral to Continued Treatment
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Enrollment
- 65
- Locations
- 1
- Primary Endpoint
- Patient Focused: Number of patients receiving services.
Study Overview
Brief Summary
This study is a collaboration between the University of Utah and Castleview Hospital in Price, Utah.
Buprenorphine is a medication approved by the FDA to treat Opioid Use Disorder (OUD). Castleview Hospital currently does not prescribe buprenorphine in the emergency department (ED) instead it refers patients to outside addiction treatment facilities. This is a service focused project which the University of Utah will provide mentoring and education to Castleview in implementing an in ED buprenorphine/naloxone distribution program along with referral to continued services. After the program has been implemented, the investigators will evaluate it using quantitative surveys of program participants and qualitative interviews of hospital staff and stakeholders.
Detailed Description
Among health care environments, ED often are the front lines of care for those with OUD or who experience opioid overdose.
The University of Utah Hospital ED has the Bridge Program which provides buprenorphine and naloxone with warm-hand off referral for continued treatment to people presenting with OUD. In order to extend the services offered by the Bridge Program to rural hospitals, the investigators will be providing mentoring and education to Castleview Hospital in establishing a similar program. Castleview Hospital is the only acute care hospital that serves Carbon and Emery counties, which outside of the Salt Lake City metro area have the highest opioid overdose rates in the State of Utah.
This project will utilize both quantitative and qualitative measures to evaluate the impact of this program on patients, hospital staff, and community members.
Study Design
- Study Type
- Observational
- Observational Model
- Other
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •For qualitative interviews with providers, administrators, stakeholders:
- •Must be affiliated with Castleview Hospital as a provider, administrator or stakeholder.
- •For the quantitative surveys:
- •Must be a Castleview Hospital patient who receives the BINDeR-Tx model.
Exclusion Criteria
- •For qualitative interviews with providers, administrators, stakeholders:
- •Not familiar with the BINDeR-Tx model
- •No interaction with the BINDeR-Tx model
- •For the quantitative surveys:
- •Unable to speak and read English
- •Subject is unable to provide contact information
Outcomes
Primary Outcomes
Patient Focused: Number of patients receiving services.
Time Frame: 24 months
Will be the aggregate number of individuals who received ED-initiated buprenorphine.
Secondary Outcomes
- Living Conditions(enrollment and 6 months post enrollment)
- Mental and Physical Health Problems and Treatment/Recovery(enrollment and 6 months post enrollment)
- Implementation and service quality: Satisfaction with projected service(24 months.)
- Substance use diagnosis and treatment(enrollment and 6 months post enrollment)
- Social Connectedness(enrollment and 6 months post enrollment)
- Implementation and service quality: Patient satisfaction(enrollment and 6 months post enrollment)
- Discharge status(enrollment and 6 months post enrollment)
- Follow-up Status(enrollment and 6 months post enrollment)
- Legal Status(enrollment and 6 months post enrollment)
- Education, Employment, and Income(enrollment and 6 months post enrollment)
Investigators
Jerry Cochran
Associate Professor
University of Utah